Cardarine (GW501516) and SR-9009 (stenabolic) recur constantly in fitness and endurance content as 'exercise in a pill' — compounds said to boost stamina, shift the body toward fat-burning and let users perform like they trained harder than they did. They are frequently lumped in with SARMs but are pharmacologically different: cardarine is a PPARδ agonist and SR-9009 is a REV-ERB agonist, both metabolic modulators that alter how muscle uses fuel. Animal work behind the hype is real — rodents given these compounds showed enhanced running endurance.
The decisive fact about cardarine is why it never reached humans. GlaxoSmithKline developed GW501516 for metabolic and lipid disorders, but preclinical testing found it caused cancer across multiple organ systems in rats and mice during long-term (roughly two-year) dosing studies. Development was halted. Anti-doping authorities are blunt about this: USADA states it 'was pulled from clinical trials when it was found to cause cancer', has not undergone human studies, and is not legally permitted in any medication, supplement or food.
In sport, GW1516 is on the WADA Prohibited List as a metabolic modulator (category S4) and is banned at all times, in and out of competition. Athletes cannot obtain a therapeutic-use exemption because there is no approved medical use anywhere. SR-9009 sits in the same regulatory bucket of unapproved metabolic agents, with the added practical wrinkle that its oral bioavailability is poor, undermining many of the benefits marketed for oral products.
The honest summary is that the endurance data are intriguing in animals and the mechanisms are real, but 'exercise in a pill' skips over the reason humans never got these drugs. Products sold as cardarine are unapproved research chemicals with a documented carcinogenic signal, no human safety data, and — for anyone drug-tested — a guaranteed anti-doping violation.